Source MS Trust: NICE has announced that it is pausing the publication of final guidance for ocrelizumab for primary progressive
multiple sclerosis.
The final decision was due to be published on the NICE website on 31 October and would have rejected ocrelizumab as an NHS treatment for primary progressive MS on the grounds of cost-effectiveness.
The MS Trust now understands that this final decision has been postponed(link is external) while further discussions take place between the drug company and NHS England. We welcome this move as it demonstrates a willingness on both sides to engage further in the debate around this drug which could have a substantial impact on the lives of people with primary progressive MS. Read on.